ANXA4 restricts HBV replication by inhibiting autophagic degradation of MCM2 in chronic hepatitis B
ANXA4 functions as a protective factor during HBV infection. ANXA4 expression is elevated under HBV attack to restrict HBV replication by inhibiting autophagic degradation of MCM2, thereby alleviating liver injury and suppressing the CHB infection process. ANXA4 also enhances the sensitivity of CHB patients to interferon therapy. Therefore, ANXA4 is expected to be a new target for CHB treatment and prognostic evaluation.
Authors
- Limin Zhen (ORCID: https://orcid.org/0000-0002-5058-9429)
- Liang Peng (ORCID: https://orcid.org/0000-0001-6184-5750)
- Xianzhi Liu (ORCID: https://orcid.org/0000-0002-4684-0721)
- Wenxiong Xu (ORCID: https://orcid.org/0000-0002-0671-697X)
- Ying Liu (ORCID: https://orcid.org/0000-0003-2408-3712)
- Lina Wu
- Yang Luo (ORCID: https://orcid.org/0000-0003-2542-3619)
- Chan Xie (ORCID: https://orcid.org/0000-0001-6344-9380)
Institutions
- Sun Yat-sen University (CN)
- Xiamen University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Guangdong Provincial People's Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1186/s12916-024-03724-1
- Citations
- 3
- Primary Topic
- Autophagy in Disease and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.16